Denosumab

Adults with osteoporosis prescribed zoledronic acid have an increased risk for atrial fibrillation when compared with denosumab, according to a study data.

Delaying denosumab doses by more than 4 months is associated with increased risks for vertebral fracture compared with on-time injections, according to findings published in Annals of Internal Medicine.

Women with postmenopausal osteoporosis who received the monoclonal antibody romosozumab were less likely to sustain a vertebral fracture during 12 months of treatment compared with women who received placebo or alendronate, study data show.

A post hoc analysis of five randomized controlled trials suggests that older adults with osteoporosis assigned denosumab therapy were 20% less likely to experience a fall during follow-up compared with those assigned placebo, according to findings published in the Journal of Bone and Mineral Research.

Postmenopausal women with osteoporosis who received a single infusion of zoledronate after 2 to 5 years of denosumab therapy retained more than half of bone mineral density gained before stopping treatment with no increase in vertebral fractures, according to findings published in the Journal of Bone and Mineral Research.

A longer interval between denosumab injections is associated with suboptimal bone mineral density response at the spine and total hip, and strategies to improve the timely administration of denosumab in real-world settings are needed, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Older adults who discontinue denosumab are at greater risk for major osteoporotic fractures and multiple vertebral fractures than those who persist with treatment, according to findings from a real-world database analysis published in Bone.

ATLANTA — The 2019 iteration of the ACR/ARP Great Debate tackled the issue of whether anabolic therapies are appropriate for patients with glucocorticoid-induced osteoporosis.

Postmenopausal women who took denosumab for a year did experienced no significant decrease in bone mineral density after switching to alendronate, according to findings presented at the American Society of Bone and Mineral Research annual meeting.

Postmenopausal women with osteoporosis who received a regimen of three separate, 6-month cycles of daily teriparatide followed by one subcutaneous injection of denosumab experienced a moderate gain in cortical bone mineral density at 18 months that was not observed among similar women who received the standard regimen of 18 months of teriparatide followed by 18 months of denosumab, according to findings published in the Journal of Bone and Mineral Research.